Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1

In the present study, the ability of the proteasome inhibitor bortezomib (BZ), an oxidative stress-inducing agent, to sensitize acute myeloid leukemia (AML) cells to decitabine (Dacogen(®), DAC; a DNA methyltransferase inhibitor), in terms of cell viability and differentiation, was investigated. Kas...

Descripción completa

Detalles Bibliográficos
Autores principales: Mpakou, Vassiliki, Spathis, Aris, Bouhla, Anthi, Mpazani, Efthimia, Papageorgiou, Sotirios, Gkontopoulos, Konstantinos, Glezou, Eirini, Thomopoulos, Thomas, Foukas, Periklis, Pappa, Vasiliki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812574/
https://www.ncbi.nlm.nih.gov/pubmed/33488804
http://dx.doi.org/10.3892/etm.2021.9628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812574/
https://www.ncbi.nlm.nih.gov/pubmed/33488804
http://dx.doi.org/10.3892/etm.2021.9628

Ejemplares similares